Browse by author
Lookup NU author(s): Professor Margaret Bassendine,
Professor Nicola CurtinORCiD,
Dr Henry Loose,
Emeritus Professor Oliver James
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In a Phase II clinical trial, 14 consecutive, unselected patients with primary hepatocellular carcinoma were treated with a new inhibitor of thymidylate synthase, CB3717. On the basis of previously reported criteria, 6 patients were considered to have a good prognosis (Grade A) and 8 a poor prognosis (Grade B). Three Grade B patients died after only one treatment. Six patients responded (4 Grade A and 2 Grade B) with a decrease in tumour size and greater than 50% fall in serum alphafetoprotein levels; 3 of these had a greater than 1 log fall in alphafetoprotein. A further patient (Grade B) showed static disease during treatment. Thus, of 11 patients receiving two or more treatments 7 showed clinical benefit, with a median survival from start of CB3717 therapy of 46 weeks (2 still alive at 33 and 67 weeks). Our results suggest that CB3717 will be a useful new therapeutic agent in hepatocellular carcinoma. Further controlled trials are indicated to confirm these preliminary findings, using the drug both as a single agent and in combination with inhibitors of thymidine uptake by cells, which may further increase efficacy.
Author(s): Bassendine MF, Curtin NJ, Loose H, Harris AL, James OF
Publication type: Article
Publication status: Published
Journal: Journal of Hepatology
Print publication date: 01/06/1987
ISSN (print): 0168-8278
ISSN (electronic): 1600-0641
PubMed id: 2439582
Altmetrics provided by Altmetric